首页> 外文期刊>Cancer Communications >Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with N0-category nasopharyngeal carcinoma and enlarged neck lymph nodes
【24h】

Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with N0-category nasopharyngeal carcinoma and enlarged neck lymph nodes

机译:N0类鼻咽癌和颈部淋巴结肿大患者在调强放疗时代的临床治疗考虑

获取原文
           

摘要

Nasopharyngeal carcinoma (NPC) shows a high proportion of lymph node metastasis, and treatment guidelines have been developed for positive nodes. However, no irradiation guidelines have been proposed for patients with enlarged neck lymph nodes (ENLNs) that do not meet the radiological criteria of 10 mm in diameter for positive lymph nodes. This study aimed to determine the prognostic value and radiation dose for ENLNs in N0-category NPC patients treated with intensity-modulated radiotherapy (IMRT). We reviewed the medical data of 251 patients with non-metastatic, N0-category NPC treated with IMRT. Receiver operating characteristic curves were used to calculate the cut-off value of the ENLN diameter for the prediction of disease failure. The biological equivalent dose (BED) for ENLNs was calculated. Patient survival was compared between the small and large ENLN groups. Independent prognostic factors were identified using the Cox proportional hazards model. The estimated 4-year regional relapse-free survival rate was higher in patients with ENLNs ≥5.5 mm than in those with ENLNs 5.5 mm (100% vs. 98.8%, P = 0.049), whereas disease-free, overall, and distant metastasis-free survival rates were similar between the two groups. After adjusting for various factors, ENLN diameter was not identified as an independent prognostic factor (P  0.05 for all survival rates). In the subgroup analysis, patients receiving BED ≥72 Gy had a similar prognosis as patients receiving BED 72 Gy in both the small and large ENLN groups. The multivariate analysis also confirmed that BED ≥72 Gy was not associated with significantly improved prognosis in patients with N0-category NPC. A BED of 72 Gy to ENLNs is considerably sufficient to provide a clinical benefit to patients with N0-category NPC. Prospective studies are warranted to validate the findings in the present study.
机译:鼻咽癌(NPC)淋巴结转移的比例很高,并且已经为阳性淋巴结制定了治疗指南。但是,对于颈部淋巴结肿大(ENLN)不符合放射学标准的阳性淋巴结直径不超过10毫米的患者,尚未提出任何放射指南。这项研究的目的是确定接受强度调制放疗(IMRT)的N0类NPC患者的ENLN的预后价值和放射剂量。我们回顾了接受IMRT治疗的251例非转移性N0类NPC患者的医学数据。接收器工作特性曲线用于计算ENLN直径的临界值,以预测疾病失败。计算了ENLN的生物等效剂量(BED)。比较小型和大型ENLN组的患者生存率。使用Cox比例风险模型确定独立的预后因素。 ENLNs≥5.5mm的患者估计的4年区域无复发生存率高于ENLNs <5.5 mm的患者(100%vs. 98.8%,P = 0.049),而无疾病,总体和远距离两组的无转移生存率相似。在调整了各种因素后,ENLN直径未确定为独立的预后因素(所有存活率P> 0.05)。在亚组分析中,无论大小,ENLN组中接受BED≥72Gy的患者的预后与接受BED <72 Gy的患者相似。多变量分析还证实,N0类NPC患者的BED≥72 Gy与预后的明显改善无关。 BEN为72 Gy相当于ENLNs,足以为N0类NPC患者提供临床益处。保证进行前瞻性研究以验证本研究的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号